Maine
Maine’s cannabis industry has mixed feelings over federal drug reclassification
Last week’s executive order by President Trump to reclassify cannabis as a less dangerous drug is being heralded by Maine’s marijuana industry as “the most progress in cannabis policy in decades.”
But members aren’t ready to celebrate yet.
At face value, reclassifying the drug from Schedule I to Schedule III could be a boon for Maine’s two cannabis markets by opening up more opportunities for research and allowing business owners to deduct ordinary business expenses, something that is currently prohibited for businesses dealing in or “trafficking” schedule I and II substances.
Many in the industry, though, say the directive lacks teeth. It orders the U.S. Attorney General to work faster on a process that has been in the works since May 2024 but does not officially reclassify cannabis immediately.
It also does not legalize the drug, which remains illegal at that federal level, and some fear any changes could open the door for “big pharma” to take over Maine’s craft cannabis industry.
A STEP IN THE ‘RIGHT DIRECTION’
Matt Hawes near the brite tanks at his Novel Beverage Co. facility in Scarborough in July 2023: Hawes is the head of the Maine Cannabis Industry Association and owner of Novel Beverage Co., which makes THC-based drinks. (Shawn Patrick Ouellette/Staff Photographer)Matt Hawes, a founding member of the Maine Cannabis Industry Association, said he’s approaching the executive order with a sense of “cautious optimism.”
“It does appear to be another step in the direction of more appropriately placing this in the social and legal framework of our society,” Hawes said. “It has always been impossible to rationalize it as a schedule I drug. It’s still hard to rationalize it as a schedule III.”
Schedule I drugs are the most dangerous, meaning they have high abuse potential with no accepted medical use. Heroin and LSD are also schedule I drugs.
Schedule III drugs, which include ketamine and Tylenol with codeine, have recognized medical uses but moderate to low potential for abuse.
The potential for rescheduling is a “move in the right direction” that will hopefully lead to de-scheduling, said Paul McCarrier, a medical cannabis operator and advocate for Maine’s recreational and medical marijuana markets.
It’s the most progress in cannabis policy in decades, he said, and will allow more research opportunities that have so far largely been stymied by the government’s Schedule I designation.
Scientists have long described the problem as a catch-22: They can’t conduct research on cannabis until they demonstrate it has a medical use, and they can’t show the plant has a medical use until they conduct research.
In 2018, state statute established a medical cannabis research grant program, which authorized the department to provide grant money from the state’s Medical Use of Cannabis Fund to “support objective scientific research” on the plant’s medicinal uses.
So far, that fund has gone untapped, but that could change with a new designation, McCarrier said.
“Maine has another opportunity to be a leader in the cannabis industry and we should not waste it,” he said.
The Maine Office of Cannabis Policy, the state’s regulatory agency, said reducing barriers to research and the “significant tax relief” that would come from allowing tax deductions are the only two changes the program is likely to see.
“Across the past three presidential administrations, the Justice Department has taken a non-enforcement approach against state-regulated medical and adult use cannabis programs, and OCP fully expects there to be no change to that posture,” the agency said last year after the Biden administration announced plans to reclassify the drug.
A LOT TO LOSE
Tax deductions will of course create “improvement in the bottom line” for small businesses, but the change should not be seen as a win for the industry, said Mark Barnett, policy director for the Maine Craft Cannabis Association.
Rather, he said, “it’s removing something that is a truly grotesque abuse of the businesses that operate in this space.”
Barnett is hopeful that the government will eventually de-schedule the drug, which he said is the “only legal, only realistic interpretation of this agricultural product.”
But he’s also wary that the Trump administration will try to intervene in a program that has historically been left to the states to manage.
“It won’t matter if you’re in the medical market, it won’t matter if you’re in the adult-use market, it won’t matter if you’re in the CBD market. We all stand to lose a lot through federal involvement in cannabis policy,” he said.
That’s also why Hawes, of the Maine Cannabis Industry Association, isn’t more enthusiastic.
“There’s still plenty of unknowns related to this situation, but we know we’re introducing a new regulatory agency in the FDA and it’s unclear what types of regulations they may impose,” he said.
If they continue to defer to the state, the long-running small business model will likely continue.
“If they come in with an iron fist stance that everything has to be done in an FDA licensed facility,” however, “the investments that it would take to achieve those standards are likely unattainable for any business in Maine,” he said.
Hawes added that the news of possible reclassification is just the latest in what has been a “dizzying” few weeks for the cannabis industry, which is also contending with the effective re-criminalization of hemp and dealing with recent recalls of recreational product and plateauing sales. There is also a referendum petition to close the recreational market and ongoing legislative efforts to increase oversight of the medical market.
Maine
Who is raising the most money in the Maine governor’s race?
(Joe Phelan/Staff Photographer)
Candidates vying to become Maine’s next governor have until midnight Tuesday to file campaign finance reports for the first quarter of the year.
The reports will show who is best positioned to control the message in the final month-plus until the primaries. But fundraising success doesn’t always guarantee a win at the ballot box.
The reports come as a growing number of leading candidates are taking to the airwaves a head of the June 9 primaries. Five Democrats and seven Republicans are vying to replace Gov. Janet Mills, who is term limited.
As of Tuesday, Republican Jonathan Bush topped all candidates in broadcast, cable and digital advertising, having booked nearly $1.5 million in ads through the primary, the political spending tracker AdImpact said.
But Republican Garrett Mason is benefitting from about $3 million in spending by Restoration of America PAC, which is running ads targeting Gov. Janet Mills and tying Mason to President Donald Trump.
Other Republican candidates running ads are Bobby Charles ($63,000), Owen McCarthy ($43,660) and Ben Midgely ($55,000.)
Hannah Pingree tops the Democratic slate with about $564,000 in ad spending, followed by Nirav Shah ($493,000), Shenna Bellows ($462,700) and Angus King III ($299,000.)
As of Tuesday afternoon, fundraising totals were only trickling in. Public access to those reports was hampered because the Maine Commission on Governmental Ethics & Election Practices is building a new website, and glitches made some reports unviewable.
This story will be updated when more reports are filed. As of Tuesday afternoon:
- Republican Jonathan Bush reported raising about $845,000 in the first quarter, but 60% of that, $500,000, was a personal loan to his own campaign. His totals were not yet available through the new website, but his quarterly fundraising and spending was provided by ethics staff.
- Republican Robert Wessels was the only other active candidate that had filed. He raised nearly $11,600 for the quarter and has about $13,540 in cash.
This is a developing story.
Maine
Obituary: Anne Theresa Tarling
Anne Theresa Tarling
SANFORD – Anne Theresa Tarling, 74, of Sanford, Maine passed away peacefully at home on April 23, 2026, surrounded by her loving family. While our hearts are broken, we find comfort in knowing she lived a full and beautiful life rooted in love, creativity, and devotion to the people who meant the most to her.
Anne was born on April 3, 1952, in Portland, Maine, to the late Joseph and Blanche Morin. She grew up in Portland and graduated from Deering High School in 1970.
In 1980, Anne married the love of her life, Ernest Tarling. Together they built a life centered on family, laughter, and partnership. Their 45 years of marriage were filled with shared memories and a deep commitment to one another and to their family.
Anne was a talented self-taught artist who found great joy in painting and sharing her creativity with others. She proudly exhibited her work at local art shows and specialty shops, and her paintings found their way into homes near and far. Her art brought beauty and comfort to many and will continue to remind us of her for years to come.
She also enjoyed gardening, sailing the coast of Maine, and hosting family gatherings. She was known for her famous chocolate chip cookies and for never missing a birthday or special occasion.
Being a devoted Nana brought her great joy, and she cherished time spent with her family above all else.
In addition to her parents, Anne was preceded in death by her brother, Stephen Morin; her sister, Julie Pochebit, her brother-in-law, Daniel Desmond; nieces Elizabeth McKee and Alison Pochebit.
She is survived by her brother, Paul (Sue Ellen) Morin, two sisters, Cheryl Desmond and Celine (Stephen) Pochebit; her husband of 45 years, Ernest Tarling; her son, Greg (Karen) Flagg, her four daughters, Jennifer Copper, Rebecca (Frank) Zavadil, Stefenie (Matthew) Burdick, and Kendra (Justin) Dowling; her 11 grandchildren, Cody, Matthew, Jackson, Gracey, Lucas, Quinn, Beau, Shea, Ellie, Will, and Stevie; a large extended family, including many loving nieces and nephews; and her longtime best friend, Sandy Hobbs.
A funeral service will be held Saturday, May 2, at 11 a.m. at St. Martha Church, 30 Portland Road, Kennebunk, Maine, followed by a celebration of life at 12:30 p.m. at For the Love of Food + Drink at Saltwater Farm, 411 Post Road, Wells, Maine.
To share a memory or leave a message of condolence, please visit Anne’s Book of Memories Page at http://www.bibberfuneral.com.
Arrangements are in the care of Bibber Memorial Chapel, 67 Summer Street, Kennebunk, ME 04043.
Maine
Moldy Maine weed is being treating with radiation
Maine marijuana growers are increasingly using radiation and other methods to remove contaminants from their products, a process consumers are likely in the dark about.
Despite a state policy requiring remediated products to be labeled as such, Maine’s Office of Cannabis Policy is not enforcing that rule.
In response to a complaint by a dispensary owner in late February, deputy director of operations Vern Malloch acknowledged, “we are not requiring labeling of remediated or treated product,” according to records obtained through a media request.
“We plan to issue guidance on this in the near future,” Malloch wrote.
Office of Cannabis Policy Director John Hudak also told lawmakers last year that the agency hasn’t enforced remediation labeling requirements since at least November 2024.
“The Office began receiving pushback from cannabis cultivators who did not want to label their cannabis if they ‘treated’ their cannabis with radiation or ozone prior to submitting the cannabis for mandatory testing,” Hudak wrote in testimony last year.
A spokesperson for the agency declined to answer specific questions Monday, but confirmed the agency stopped enforcing the rule after some growers raised concerns over the “misleading impact” that labeling treated cannabis has on consumers.
“Requiring label disclosure of the use of irradiation or ozone treatment implies a consumer risk that is not scientifically supported and is potentially misleading in its implication about potential harm from exposure,” Alexis Soucy, OCP’s director of media relations, wrote in an email.
Over the last couple years, several marijuana products have been subjected to recall because of high levels of mold, yeast and other contaminants. Unsafe levels of mold in cannabis can cause flu-like symptoms, including respiratory issues, sinus infections, headaches and dizziness.
But rather than tossing their product, growers can turn to a process called irradiation, often involving gamma rays or X-rays, to remove contaminants.
Supporters say it’s a safe way to reduce waste and prolong shelf lives. Mold and yeast grow naturally just about everywhere and many species are benign. Standard cannabis mold testing does not differentiate between harmful and harmless microbes.
Opponents, however, argue there isn’t enough research about remediating cannabis to say whether it’s safe or not. There is not much data on whether the various types of remediation are effective at killing microbes or are safe for consumers, most of whom don’t know about the practice.
“It’s a complex topic without many answers,” said Yasha Kahn, who co-founded MCR Labs, one of four licensed cannabis testing facilities in Maine. “Hopefully, the rescheduling can lead to more research.”
The federal government moved last week to reclassify cannabis from a Schedule I to Schedule III drug. Decades-long restrictions on cannabis research will be lifted, which acting Attorney General Todd Blanche said will allow for studies into “marijuana’s safety and efficacy.”
Kahn, who operates several testing labs throughout New England, said irradiating cannabis has become increasingly prevalent in legal markets across the country and the world. It’s still debated whether irradiation works as well as it’s supposed to, he said.
‘THIS IS A FAIRLY NEW PROCESS’
There are numerous kinds of cannabis remediation, each with its own pros and cons. Growers most commonly use X-rays, gamma radiation or ozone gas to remove mold and microbes.
Radiation does not kill all the mold, yeast and other microbes present in cannabis outright, Kahn said. Certain species of mold, like harmful mycotoxins, can often survive remediation. Others can remain dormant for months following the procedure.
“Irradiation gets rid of mold’s ability to procreate, and not necessarily permanently,” he said. “You can take that same product and test it again, months from then, and there’s going to be mold growth.”
Some in the industry, like organic marijuana farmer Lizzy Hayes in Mercer, fear that having the option to remediate cannabis removes the incentive to grow clean cannabis. If you can simply use radiation to eliminate mold from harvested crops, she said, why would you put effort into growing mold-free products?
Part of the blame, according to Hayes, lies at the feet of Maine’s recreational cannabis testing regime. Unlike the state’s medical marijuana market, batches of recreational cannabis products must be tested for contaminants like mold, yeast and heavy metals before they can be put on a dispensary shelf.
But since the mold test only detects the presence of mold, not whether it’s harmful, Hayes said many growers save themselves the trouble and irradiate their cannabis by default rather than risking a failed test.
“When you have a regulatory system that incentivizes irradiation, it’s also making it so that customers don’t have access to as high quality of a product,” she said.
Some in the industry disagree. A bill was proposed last year to codify requirements around labeling treated cannabis and inspecting remediation equipment. It was ultimately defeated after many Maine cannabis growers testified in opposition to the bill.
“Radiation and ozone treatment methods are well-established, scientifically validated technologies commonly used in industries far beyond cannabis,” wrote Jacob Racioppi, owner of Goose River Cannabis in Unity. “In fact, they are standard in the food industry.”
Joel Pepin, co-founder of JAR Cannabis Company, owns and operates one of about a dozen X-ray machines in Maine’s cannabis industry. He estimated that about half of Maine’s recreational cannabis has been treated by similar methods. It would be overkill, he said, to require all of that product to be labeled over scientifically unfounded concerns.
“If we apply this same logic to other industries in Maine, then why doesn’t this bill also require dental patients to wear a shirt that says, ‘treated by X-ray’ after leaving the dental office?” Pepin testified.
Neither Racioppi nor Pepin responded to requests for an interview.
Lorri Maling, laboratory director at cannabis testing facility Nelson Analytical, seconded Pepin that remediating cannabis is “more in use now than it was a few years ago.”
While some opponents of irradiation claim the process reduces THC content and eliminates terpenes — the chemicals that give different cannabis strains unique scents and effects — Maling said there’s no data to back that up. Nor is there much data to back up many other conclusions about the effects of irradiating cannabis.
Most of the studies on the effects of irradiation have been on fruits and vegetables, she said, which have not shown any negative effects — though there’s no guarantee that any remediation method will kill all bacteria.
“This is a fairly new process for cannabis,” Maling wrote in an email. “I really cannot say that it is safe or unsafe for cannabis as there really is not enough data on this.”
-
New York14 minutes agoFather and Daughter Who Sold Fake Warhols Plead Guilty in Forgery Scheme
-
Detroit, MI44 minutes agoJackson Jobe throws first bullpen in return from Tommy John surgery
-
San Francisco, CA56 minutes ago
Oakland, California, airport can use ‘San Francisco’ in name after settlement
-
Dallas, TX1 hour ago
Cowboys LB coach ‘feels really good’ after NFL draft, new additions
-
Miami, FL1 hour ago2 more Miami Beach Commissioners endorse Vicki Lopez for Miami-Dade Commission
-
Boston, MA1 hour ago99 Restaurant in Charlestown may close for apartments
-
Denver, CO1 hour agoRe/Max to be sold, headquarters to leave Denver
-
Seattle, WA1 hour agoSeattle’s drug diversion plan falters as open-air use persists in neighborhood hotspots